Imesol

Etoricoxib, the active ingredient in Imesol, is a COX-2 inhibitor presented as an oral formulation for systemic use. It is indicated for the management of inflammatory joint disorders and acute pain in adult patients.

GNH USA supplies Imesol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imesol (etoricoxib) belongs to the COX‑2 selective NSAID class and is used to treat inflammatory and painful musculoskeletal conditions. - Osteoarthritis: reduces joint pain and improves functional mobility. - Rheumatoid arthritis: alleviates inflammation and joint swelling. - Ankylosing spondylitis: diminishes spinal stiffness and pain. - Acute pain: provides rapid analgesia for short‑term severe pain. - Dental pain: controls postoperative dental discomfort.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Gastrointestinal discomfort: mild nausea, dyspepsia, or abdominal pain. - Headache: transient tension‑type headaches. - Edema: peripheral swelling, especially of the lower limbs.

Serious or Rare Side Effects: - Cardiovascular thrombotic events: increased risk of myocardial infarction or stroke. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Gastrointestinal ulcer or bleeding: serious bleeding in the stomach or intestines.

Patients should be evaluated for individual risk factors before initiating therapy. - Cardiovascular risk assessment: consider history of heart disease before use. - Blood pressure monitoring: check regularly during treatment. - Renal and hepatic function: evaluate baseline labs and monitor periodically. - Elderly caution: start at the lowest effective dose and monitor for adverse effects. - Hypersensitivity avoidance: discontinue if signs of allergic reaction appear. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Etoricoxib may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Warfarin: increased bleeding risk. - Other NSAIDs or COX‑2 inhibitors: heightened gastrointestinal and cardiovascular toxicity. - Anticoagulants (e.g., dabigatran): potential for severe bleeding. - Lithium: elevated lithium serum concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible reduction in antihypertensive effect. - Diuretics: risk of renal function decline. - Methotrexate: may increase methotrexate levels and toxicity.